Rezvoglar Approved as Second Interchangeable Insulin

The FDA has approved Eli Lilly’s Rezvoglar (insulin glargine-aglr) as the second interchangeable biosimilar insulin on the U.S. market.

With the approval, Rezvoglar joins Mylan’s Semple (insulin glargine-yfgn) as a lower-cost option that pharmacists can substitute for Sanofi’s Lantus (insulin glargine) without a change in the original prescription.

The availability of biosimilar and interchangeable insulin products can potentially lower treatment costs and enable greater access for patients, the agency said.